1. Introduction {#sec1}
===============

In December 2019, several patients with a pneumonia of unknown etiology were treated in Wuhan, China. By late December 2019, a novel coronavirus originally named 2019-nCoV was found to be the etiology of these illness. The terminology was later updated by the WHO whereby the disease is named COVID-19 and it is caused by the virus SARS-CoV-2 \[[@bib1],[@bib2]\]. On January 21, 2020, the Department of Infectious Disease at the Fifth Medical Center of Chinese PLA General Hospital was designated to be one of the medical institutions for the diagnosis and treatment of patients with COVID-19 in Beijing, China. On February 24, 2020, the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) reported that 13.8% of those infected with COVID-19 had severe disease, with a case fatality rate of 3.8%. As of April 3, 2020, the case fatality rate of COVID-19 in China is approximately 4.0% \[[@bib3]\]. At this time, the epidemic situation across China has been effectively controlled, and most of the new cases in China are currently imported from abroad. This study aims to evaluate the characteristics and prognostic factors of disease severity in patients with COVID-19 in Beijing.

1.1. Patients and methods {#sec1.1}
-------------------------

This study evaluated the characteristics and prognostic factors of disease severity in 63 confirmed non-imported COVID-19 patients in Beijing. Diagnostic criteria for COVID-19 pneumonia was based on the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China \[[@bib4]\]. Various specimens including respiratory samples from throat swab or sputum, urine, blood or stool samples were collected and tested for SARS-CoV-2 following WHO guidelines for quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) \[[@bib5],[@bib6]\]. Positive results of COVID-19 infection were defined as any positive test from the above specimens. Routine serial hematologic and biochemical tests were performed after admission, and the serum samples were screened for common respiratory pathogens, including antibodies to adenovirus, chlamydia pneumoniae, mycoplasma pneumoniae, respiratory syncytial virus, coxsackie virus A16, legionella pneumophila and mycobacterium tuberculosis and all were negative. Chest X-Ray and chest CT scans were obtained for all patients and monitored serially.

Data were analyzed with SPSS V.21.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as the mean ± standard deviation (SD) or as the median (range). The analysis of variance or Kruskal-Wallis rank sum test was used for comparison between multiple groups. Categorical variables were expressed as a number (%). Intergroup comparison was performed using chi-square test. Spearman correlation coefficient was used to describe the association between different variables and adverse events. The logistic regression model was used to identify factors associated with adverse events. Odds ratios and their associated 95% confidence intervals (CIs) were used as measures of effect size. p value less than 0.05 (two-tailed) was considered to be statistically significant.

1.2. Clinical characteristics {#sec1.2}
-----------------------------

Patients were categorized into mild, moderate, severe and critically ill levels of severity based on the criteria shown in [Table 1](#tbl1){ref-type="table"} . Eight patients were identified to have mild disease (12.7%), 36 had moderate disease (57.1%), 10 had severe diseases (15.9%) and nine were critically ill (14.3%). Patients with severe or critical disease accounted for 30.2%. [Table 2](#tbl2){ref-type="table"} shows the demographic, epidemiologic, and clinical features of patients at admission. The median patient age was 47 years, with a range of 3--85 years of age. [Fig. 1](#fig1){ref-type="fig"} shows the age and demographic characteristics of patients with COVID-19. COVID-19 preferentially affects males (37 of 63, 58.7%). The sex distribution for the various levels of severity showed that among the mild cases, 7 (87.5%) were male, among moderate cases, 19 (52.8%) were male, among severe cases, 6 (60.0%) were male and among critically ill patients, 5 (55.6%) were male ([Fig. 2](#fig2){ref-type="fig"} ). There was a statistically significant difference among the four groups (p \< 0.001).Table 1Defining level of severity in COVID-19.Table 1Clinical categoryDefinition**Mild disease**Mild symptoms and normal or non-pneumonia findings on radiographic examination**Moderate disease**Respiratory symptoms and fever, with evidence of pneumonia on radiographic examination**Severe disease**Dyspnea, respiratory frequency ≥30/minute, blood oxygen saturation ≤93%, PaO2/FiO2 ratio \<300, and/or lung infiltrates \>50% of the lung field within 24--48 h**Critically ill**Respiratory failure and mechanical ventilation required, septic shock, and/or multiple organ dysfunction/failure and requires ICU monitoring and treatmentTable 2Demographic and epidemiologic characteristics of patients with COVID-19 in beijing.Table 2CharacteristicMild disease (n = 8)Moderate disease (n = 36)Severe disease (n = 10)Critically ill (n = 9)Total (n = 63)p valueMedian age (range)23 (3, 48)47 (13, 78)59 (33, 85)63 (34, 79)47 (3, 85)0.000BMI23.40 ± 4.9824.09 ± 3.1425.95 ± 3.1725.13 ± 3.2024.45 ± 3.430.338EpidemiologicTravel history to Wuhan in 14 days before the onset8 (100.0%)22 (61.1%)2 (20.0%)3 (33.3%)35 (55.6%)0.017History of contact with a person from Wuhan or around Wuhan in the 14 days before onset2 (25.0%)17 (47.2%)4 (40.0%)3 (33.3%)26 (41.3%)0.602Contact with a confirmed case of COVID-19 infection3 (37.5%)24 (66.7%)3 (30.0%)4 (44.4%)34 (54.0%)0.549Case clustering2 (25.0%)25 (69.4%)5 (50.0%)4 (44.4%)36 (57.1%)0.363Symptoms, n (%)Fever4 (50.0%)35 (97.2%)7 (70.0%)7 (77.8%)53 (84.1%)0.004Chills01 (2.8%)001 (1.6%)0.182Myalgia1 (12.5%)9 (25.0%)2 (20.0%)4 (44.4%)16 (25.4%)0.461Cough2 (25.0%)21 (58.3%)5 (50%)6 (66.7%)34 (54.0%)0.256Headache07 (19.4%)1 (10.0%)08 (12.7%)0.260Anorexia1 (12.5%)11 (30.6%)2 (20%)3 (33.3%)17 (27.0%)0.678Sputum production09 (25.0%)6 (60.0%)4 (44.4%)19 (30.2%)0.029Shortness of breath01 (2.8%)4 (40.0%)6 (66.67%)11 (17.5%)0.000Dizziness1 (12.5%)5 (13.9%)01 (11.1%)7 (11.1%)0.671Diarrhea04 (11.1%)1 (10.0%)05 (7.9%)0.549Sore throat2 (25%)9 (25.0%)1 (10.0%)05 (7.9%)0.301Runny nose01 (2.8%)001 (1.6%)0.068Fig. 1Age and clinical type distribution of COVID-19.Fig. 1Fig. 2Sex distribution of COVID-19 with different clinical classification.Fig. 2

The mean BMI of the 63 patients was 24.45 ± 3.43, and there was no statistically significant difference among the four groups. Thirty-five patients (55.6%) had a travel history to Wuhan in the 14 days before the onset of symptoms, and twenty-six (41.3%) patients without a travel history to Wuhan had a history of contact with a person from or near Wuhan in the 14 days before the onset of illness. Thirty-four (54.0%) of 63 patients had close contact with patients with COVID-19 and 36 (57.1%) had a history of family clustering.

Patients with coexisting conditions were more susceptible to severe disease and 29 of our 63 patients had 1 or more coexisting diseases, including hypertension in 12 cases, diabetes mellitus in 5, cerebral infarction in 2, cardiac arrhythmia in 2, prostate cancer in 1, bronchial asthma in 2, pulmonary tuberculosis in 1, claustrophobia in 1, thyroid disease in 3, chronic hepatitis in 2, and chicken pox in 1. This is shown in [Table 3](#tbl3){ref-type="table"} . The most common symptoms were fever (84.1%) and cough (54.0%), but diarrhea was not common.Table 3Comorbidities of patients with COVID-19.Table 3ComorbiditiesMild diseaseModerate diseaseSevere diseaseCritically illHypertension--813Diabetes mellitus--221Cerebral infarction------2Cardiac arrhythmia----11Prostate cancer----1--Bronchial asthma--11--Pulmonary tuberculosis1------Claustrophobia------1Thyroid disease12----Liver disease----1 (Hepatitis B)1 (NAFLD)Chicken pox--1----[^2]

1.3. Laboratory features {#sec1.3}
------------------------

Laboratory tests on admission showed leukopenia in 11 patients (17.5%), lymphopenia in 11 patients (17.5%), thrombocytopenia in 3 patients (4.8%), anemia in 10 patients (15.9%), and eosinopenia in 30 patients (47.6%) ([Table 4](#tbl4){ref-type="table"} ). The leukocyte, neutrophil, lymphocyte, eosinophil counts and hemoglobin level differed significantly among the four severity groups. Eosinopenia was not found in patients with mild disease but was found in 19 patients (52.8%) with moderate disease, 7 patients (70.0%) with severe disease and 4 critically ill patients (44.4%).Table 4Laboratory findings in Patients with COVID-19 at admission.Table 4Laboratory FindingMild disease (n = 8)Moderate disease (n = 36)Severe disease (n = 10)Critically ill (n = 9)Total (n = 63)p valueLeukocyte count, 10^9^ cells/L5.92 ± 1.294.56 ± 1.21 [d](#tbl4fnd){ref-type="table-fn"}^\#^5.01 ± 1.766.84 ± 3.575.13 ± 1.950.007Neutrophil count, 10^9^ cells/L3.25 ± 0.82 [c](#tbl4fnc){ref-type="table-fn"}^\#^2.70 ± 1.01 [d](#tbl4fnd){ref-type="table-fn"}^\#^3.76 ± 1.85 [f](#tbl4fnf){ref-type="table-fn"}\*5.54 ± 3.703.32 ± 1.960.001Lymphocyte count, 10^9^ cells/L2.00 ± 0.64 [a](#tbl4fna){ref-type="table-fn"}^.^[b](#tbl4fnb){ref-type="table-fn"}^.^[c](#tbl4fnc){ref-type="table-fn"}^\#^1.42 ± 0.56 [d](#tbl4fnd){ref-type="table-fn"}^.^[e](#tbl4fne){ref-type="table-fn"}^\#^0.90 ± 0.470.83 ± 0.501.32 ± 0.650.001Hemoglobin level, g/L144.88 ± 12.63 [c](#tbl4fnc){ref-type="table-fn"}^\#^137.67 ± 14.07 [e](#tbl4fne){ref-type="table-fn"}^\#^134.5 ± 16.79119.33 ± 30.85135.46 ± 18.590.021Platelet count, 10^9^ cells/L204.38 ± 49.16180.31 ± 56.84183.40 ± 71.87193.56 ± 75.86185.75 ± 60.500.759Eosinophils count, 10^9^ cells/L0.14 ± 0.06 [a](#tbl4fna){ref-type="table-fn"}^.^[b](#tbl4fnb){ref-type="table-fn"}^.\#^0.03 ± 0.04^5^\*0.01 ± 0.00 [f](#tbl4fnf){ref-type="table-fn"}\*0.09 ± 0.140.05 ± 0.070.000Monocytes count, 10^9^ cells/L0.46 ± 0.160.55 ± 0.990.33 ± 0.190.37 ± 0.190.48 ± 0.750.835PT, s12.01 ± 1.13 [c](#tbl4fnc){ref-type="table-fn"}\*12.14 ± 0.81 [e](#tbl4fne){ref-type="table-fn"}\*12.57 ± 2.19 [f](#tbl4fnf){ref-type="table-fn"}\*21.30 ± 8.2913.52 ± 9.630.072PTA (%)88.97 ± 23.3384.04 ± 15.13 [e](#tbl4fne){ref-type="table-fn"}\*84.18 ± 23.1066.97 ± 28.3582.14 ± 20.280.097Fibrinogen, g/L2.04 ± 0.39 [a](#tbl4fna){ref-type="table-fn"}^.^[b](#tbl4fnb){ref-type="table-fn"}^.^[c](#tbl4fnc){ref-type="table-fn"}\*3.14 ± 1.003.69 ± 2.043.62 ± 1.523.18 ± 1.320.045D-dimer, mg/L0.16 ± 0.06 [b](#tbl4fnb){ref-type="table-fn"}^.^[c](#tbl4fnc){ref-type="table-fn"}^\#^0.35 ± 0.25 [d](#tbl4fnd){ref-type="table-fn"}^.^[e](#tbl4fne){ref-type="table-fn"}^\#^3.15 ± 3.311.95 ± 2.381.97 ± 1.830.000Sodium level, mmol/L137.14 ± 3.08137.66 ± 3.30136.40 ± 3.10135.22 ± 4.82137.03 ± 3.520.288Potassium level, mmol/L4.64 ± 0.31 [a](#tbl4fna){ref-type="table-fn"}^.^[b](#tbl4fnb){ref-type="table-fn"}^.\#^4.14 ± 0.393.97 ± 0.604.26 ± 0.524.18 ± 0.470.020Albumin level, g/L43.62 ± 3.20 [a](#tbl4fna){ref-type="table-fn"}\*^.^[b](#tbl4fnb){ref-type="table-fn"}^\#.^[c](#tbl4fnc){ref-type="table-fn"}^\#^39.47 ± 4.09 [e](#tbl4fne){ref-type="table-fn"}^\#^36.80 ± 6.2932.77 ± 5.1738.61 ± 5.380.000Globulin level, g/L28.63 ± 2.3929.03 ± 4.8129.30 ± 4.6928.00 ± 4.3028.87 ± 4.410.919Total bilirubin level, mmol/L12.14 ± 9.9812.09 ± 6.8812.14 ± 4.2910.83 ± 5.5311.92 ± 6.690.965ALT level, U/L29.88 ± 20.7329.39 ± 19.40 [e](#tbl4fne){ref-type="table-fn"}\*41.50 ± 47.5883.11 ± 140.4939.05 ± 59.030.100AST level, U/L31.00 ± 17.00 [c](#tbl4fnc){ref-type="table-fn"}\*29.61 ± 15.24 [e](#tbl4fne){ref-type="table-fn"}^\#^40.10 ± 27.60 [f](#tbl4fnf){ref-type="table-fn"}\*95.67 ± 153.6540.89 ± 61.990.034ALP level, U/L97.50 ± 53.377.00 ± 43.1066.30 ± 20.5373.00 ± 35.9377.33 ± 40.890.436GGT level, U/L23.25 ± 13.83 [b](#tbl4fnb){ref-type="table-fn"}^.^[c](#tbl4fnc){ref-type="table-fn"}\*34.28 ± 27.6553.30 ± 45.8954.89 ± 29.3038.84 ± 31.370.061LDH level, U/L231.75 ± 122.92 [c](#tbl4fnc){ref-type="table-fn"}^\#^217.47 ± 51.12 [e](#tbl4fne){ref-type="table-fn"}^\#^279.70 ± 84.36 [f](#tbl4fnf){ref-type="table-fn"}\*376.89 ± 161.55251.94 ± 103.510.000Creatine phosphokinase level, U/L80.75 ± 28.93101.55 ± 124.69132.57 ± 111.91137.00 ± 166.51109.68 ± 122.790.826Urea level, mmol/L4.33 ± 0.67 [c](#tbl4fnc){ref-type="table-fn"}^\#^3.99 ± 1.21 [e](#tbl4fne){ref-type="table-fn"}^\#^4.49 ± 1.05 [f](#tbl4fnf){ref-type="table-fn"}^\#^9.41 ± 8.694.88 ± 3.780.001Creatinine level, μmol/L77.13 ± 21.33 [c](#tbl4fnc){ref-type="table-fn"}^\#^77.3 ± 12.92 [e](#tbl4fne){ref-type="table-fn"}^\#^74.80 ± 10.99 [e](#tbl4fne){ref-type="table-fn"}^\#^103.11 ± 48.3180.57 ± 23.470.017C-reactive protein level, mg/L5.08 ± 8.58 [b](#tbl4fnb){ref-type="table-fn"}^\#^11.83 ± 17.07^4\#^48.92 ± 72.7130.96 ± 29.4619.53 ± 35.940.012Erythrocyte sedimentation rate, mm/60min5.14 ± 4.1^1^\*[b](#tbl4fnb){ref-type="table-fn"}^\#.^[c](#tbl4fnc){ref-type="table-fn"}^\#^25.16 ± 21.28 [d](#tbl4fnd){ref-type="table-fn"}\*[e](#tbl4fne){ref-type="table-fn"}^\#^45.86 ± 19.0752.13 ± 37.4629.24 ± 26.370.001Serum ferritin (Times the upper limit of normal)0.55 ± 0.50^2.^[c](#tbl4fnc){ref-type="table-fn"}^\#^2.00 ± 2.20 [e](#tbl4fne){ref-type="table-fn"}^\#^3.20 ± 1.475.08 ± 3.292.45 ± 2.480.000IL-6 level, pg/ml5.26 ± 1.25^2.^[c](#tbl4fnc){ref-type="table-fn"}^\#^14.17 ± 11.37 [d](#tbl4fnd){ref-type="table-fn"}^\#^[e](#tbl4fne){ref-type="table-fn"}\*33.22 ± 31.9034.09 ± 26.4718.50 ± 20.030.001[^3][^4][^5][^6][^7][^8][^9][^10]

Lymphocyte subset analysis ([Table 5](#tbl5){ref-type="table"} ) showed that CD4^+^, CD8^+^ T lymphocytes and B lymphocytes were significantly decreased in severe and critically ill patients. Natural killer (NK) cells, a key component of innate immunity against infection \[[@bib7]\], trended lower with increasing severity, but there was no statistically significant difference among the four groups. Prothrombin time (PT) and prothrombin activity (PTA) did not significantly differ among the four groups, but fibrinogen (FIB) and D-dimer levels showed a statistically significant difference, in that the levels were much lower in the mild and moderate disease group compared with the severe disease groups.Table 5Lymphocyte Subsets levels in patients with COVID-19.Table 5Laboratory findingMild diseaseModerate diseaseSevere diseaseCritically illTotalp valueLymphocyte count, cells/μl1767.57 ± 587.82 [a](#tbl5fna){ref-type="table-fn"}^.^[b](#tbl5fnb){ref-type="table-fn"}^.^[c](#tbl5fnc){ref-type="table-fn"}^\#^1202.35 ± 483.66 [e](#tbl5fne){ref-type="table-fn"}\*861.50 ± 464.96746.88 ± 503.441172.49 ± 560.250.001T lymphocyte count, cells/μl1210.75 ± 408.81 [a](#tbl5fna){ref-type="table-fn"}^.^[b](#tbl5fnb){ref-type="table-fn"}^.^[c](#tbl5fnc){ref-type="table-fn"}^\#^808.97 ± 371.22 [d](#tbl5fnd){ref-type="table-fn"}\*[e](#tbl5fne){ref-type="table-fn"}^\#^522.57 ± 318.73464.67 ± 339.68778.98 ± 417.650.000CD4 T lymphocyte count, cells/μl689.38 ± 251.29 [a](#tbl5fna){ref-type="table-fn"}^.^[b](#tbl5fnb){ref-type="table-fn"}^.^[c](#tbl5fnc){ref-type="table-fn"}^\#^436.8 ± 225.08 [d](#tbl5fnd){ref-type="table-fn"}\*[e](#tbl5fne){ref-type="table-fn"}^\#^257.86 ± 129.48270.11 ± 162.75425.36 ± 242.550.000CD8 T lymphocyte count, cells/μl462.88 ± 154.43 [b](#tbl5fnb){ref-type="table-fn"}^.^[c](#tbl5fnc){ref-type="table-fn"}^\#^355.33 ± 166.86 [d](#tbl5fnd){ref-type="table-fn"}\*[e](#tbl5fne){ref-type="table-fn"}^\#^205.14 ± 153.09202.22 ± 199.10330.43 ± 184.260.004B lymphocyte count, cells/μl330.71 ± 177.65 [a](#tbl5fna){ref-type="table-fn"}^.^[b](#tbl5fnb){ref-type="table-fn"}^.^[c](#tbl5fnc){ref-type="table-fn"}^\#^148.92 ± 89.33128.83 ± 42.44119.38 ± 59.07164.71 ± 113.660.000NK cell count, cells/μl288 ± 175.93203.63 ± 209.433185.00 ± 180.11102.88 ± 72.28196.14 ± 189.030.310CD4/CD8 ratio1.53 ± 0.411.62 ± 1.861.28 ± 0.762.42 ± 1.561.63 ± 1.570.671[^11][^12][^13][^14][^15][^16][^17]

Alanine aminotransferase (ALT) levels were elevated in 16 patients (25.4%), aspartate transaminase (AST) levels were elevated in 14 patients (22.2%), alkaline phosphatase levels (ALP) were elevated in 3 patients (4.8%), and gamma-glutamyl transferase (GGT) was elevated in 21 patients (33.3%), but only AST level had statistically significant difference among the four groups (p = 0.034). Albumin level was decreased in 11 patients (17.5%), lactate dehydrogenase (LDH) levels were increased in 26 patients (41.3%), and both of albumin and LDH levels showed a statistically significant difference among the four groups. Both creatinine and urea levels were increased in patients with severe diseases, and there were significant differences between the four groups.

Creatine phosphokinase, which is mainly found in cardiac myocytes, was elevated in 25 patients (39.7%). Though there was no statistically significant difference in these four different clinical classifications, the levels of creatine phosphokinase in the severe and critically ill groups were much higher than in the mild and moderate patients.

C-reactive protein level (CRP), erythrocyte sedimentation rate (ESR), serum ferritin and interleukin-6 (IL-6) levels all had a significant elevation in the severe and critically ill groups.

1.4. Radiographic features {#sec1.4}
--------------------------

On admission, all patients in the mild group had normal imaging. Ground-glass opacities were found in the remaining 55 cases. Seven moderately ill patients had single lobe focal ground-glass opacities and 4 moderately ill patients had multiple unilateral ground-glass opacities. Twenty-four moderately ill patients, 10 severely ill patients and 9 critically ill patients had diffuse multiple bilateral ground-glass opacities. Pleural effusions were found in 1 case with moderate illness, 3 with severe illness and 4 patients who were critically ill ([Table 6](#tbl6){ref-type="table"} ).Table 6Radiographic features in patients with COVID-19.Table 6Radiographic featuresMild disease (n = 8)Moderate disease (n = 36)Severe disease (n = 10)Critically ill (n = 9)No Ground-glass opacities (GGO)8000Single lobe Focal GGO0703Multiple unilateral GGO0400Multiple bilateral GGO024109Consolidation0832Pleural effusion0134Peripheral lung distribution01342

1.5. Clinical outcomes {#sec1.5}
----------------------

Patients were categorized into two groups according to clinical outcome, defined by those with or without an adverse event. Adverse events were defined as any of the following: respiratory rates ≥30 breaths per minute, PaO2/FiO2 ≤300 mmHg, peripheral oxygen saturation (SpO2) ≤93%, or admission to the intensive care unit. The group with adverse events includes patients with severe disease or who are critically ill.

[Fig. 3](#fig3){ref-type="fig"} shows the relationships between clinical characteristics and disease severity, using the Spearman correlation coefficient. The following variables showed significant positive correlation to the disease severity (p \< 0.01): advanced age, sputum production, shortness of breath, higher neutrophil count, AST level (p \< 0.05), LDH level, GGT level, CRP level, ESR level, serum ferritin level and interleukin-6. Of these, D-dimer, and serum ferritin level had a particularly strong correlation. There was also a positive correlation between ferritin levels and liver function tests ([Table 7](#tbl7){ref-type="table"} ). Patients with higher total lymphocyte count (p \< 0.01), T lymphocyte count (p \< 0.01), CD8^+^ T lymphocyte count (p \< 0.01), CD4^+^ T lymphocyte count (p \< 0.01), B lymphocyte count (p \< 0.05), albumin level (p \< 0.01), and sodium level (p \< 0.05), were negatively correlated with disease severity, and a travel history to Wuhan in the 14 days prior to the onset of disease was also negatively correlated with disease severity (p \< 0.01).Fig. 3Correlation coefficient and p value between clinical characteristics and disease severity.Fig. 3Table 7Correlation coefficient and p value between liver enzymes and serum ferritin.Table 7ParameterSpearman correlation coefficientp valuesALT0.3850.002AST0.4370.000ALP−0.0540.673GGT0.2040.109LDH0.3940.001

The variables which showed a significant correlation with disease severity were included in a binary logistic regression model to identify that C-reactive protein level, CD8^+^ T lymphocyte count, and D-dimer were independent predictors of disease severity ([Table 8](#tbl8){ref-type="table"} ).Table 8Independent predictors of disease severity by multivariate Cox regression.Table 8ParameterOdds Ratio95% CIp valueC-reactive protein level1.0731.013--1.1360.017CD8 T lymphocyte count0.9890.979--1.0000.043D-dimer5.3130.325--86.8160.241

2. Discussion {#sec2}
=============

The identification of predictive variables may assist physicians in the evidence-based treatment of COVID-19. We analyzed the demographic, clinical, laboratory and imaging features of 63 patients with COVID-19 in Beijing to determine potential biomarkers that may affect the prognosis and management of these patients.

COVID-19 can occur in any age group. Our data showed that mild illness appears predominately in those under 30 years of age. Older individuals develop higher levels of severity of disease. Overall, we showed that there was a slight male predominance. Laboratory analysis at the time of admission in our cohort of patients demonstrated that lymphocyte and eosinophil counts were significantly decreased in patients with severe disease (p = 0.001 and p = 0.000, respectively). Eosinopenia was not found in mild disease, but was present in 52.8%, 70% and 44.4% of patients with moderate, severe and critical illness. Evaluation of lymphocytes subsets demonstrated that CD4^+^, CD8^+^ T lymphocytes and B lymphocytes were both reduced in severe disease and critically ill patients. Natural killer (NK) cell counts were on a downward trend with increasing severity, but there was no statistical difference among the four groups.

Adam et al. reported that in patients with acute exacerbations of chronic obstructive pulmonary disease, eosinopenia increases the risk of treatment failure and in-hospital mortality \[[@bib8]\]. Other studies have also demonstrated eosinopenia in late stage bacterial pneumonias, as well as COVID-19 \[[@bib9]\]. This is consistent with our results of eosinopenia in more severely affected patients.

It has been shown that both SARS-CoV-1 and SARS-CoV-2 use the same angiotensin-converting enzyme 2 (ACE2) receptor to enter host cells \[[@bib10],[@bib11]\]. The pathophysiology following viral entry is under intense study, and our data showed the total T lymphocytes, CD4^+^, CD8^+^ T lymphocytes and B lymphocyte counts were all significant decreased in severe and critically ill patients on admission. These immunological characteristics were also seen in SARS-CoV-1 infection \[[@bib12]\]. These results indicate that SARS-CoV-2, like its predecessor has a negative impact on T-cell mediated immunity \[[@bib13]\].

In other viral infections, such as HIV, CD4^+^ lymphocytes have been found to migrate to various tissues such as lymph nodes and bone marrow, supporting the theory that homing of CD4^+^ or CD8^+^ lymphocytes may be responsible for depletion of these cells in the peripheral blood \[[@bib14]\]. In dengue virus, T cells have been capable of skin homing \[[@bib15]\]. So the possibility exists that the reason for the lymphopenia in COVID-19 could be the result of homing of lymphocyte subsets to the lung, although the actual clinical evidence for this has yet to be uncovered.

Liver injury in patients with SARS-CoV-2 infection is not rare \[[@bib16]\]. We found that ALT levels were elevated in 25.4% of patients, AST elevated in 22.2%, ALP elevated in 4.8%, and GGT elevated in 33.3% of patients, although only AST level was much higher in the critically ill patients and showed significance difference among the four groups. However, albumin level was much lower and LDH levels were much higher in the severity patients, and there was a statistically significant difference among the four groups (p = 0.000 and p = 0.000). Of these 63 patients, only two had a history of liver disease with normal liver function, one with hepatitis B undergoing antivirus treatment, the other with NAFLD.

We found that the inflammatory markers CRP level, ESR, serum ferritin and interleukin-6 levels were elevated in severe and critically ill groups, and that serum ferritin level was positively associated with ALT, AST and LDH levels, but not with ALP and GGT. Serum ferritin levels can be affected by iron status and may indicate a hyperimmune state. It is a marker for hemophagocytic lymphohistiocytosis \[[@bib17],[@bib18]\], which is a known complication of viral infections. It is often accompanied by an increase in certain cytokines such as IL-2Rα \[[@bib19]\]. Serum ferritin has been found to correlate with the presence of or severity of disease in other diseases states, including inflammatory conditions such as macrophage activation syndrome \[[@bib20]\].

Severe disease, characterized by massive alveolar damage and progressive respiratory failure, may be related to a cytokine storm event \[[@bib21]\]. In cytokine storm, increases in interleukin (IL)-2, IL-7, granulocyte colony stimulating factor (G-CSF), interferon-γ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumor necrosis factor-α may be observed. In addition to the above cytokines, the pro-inflammatory cytokines such as IL-1β and IL-6 are often significant contributors to the host response to infections and increased morbidity and mortality \[[@bib22]\]. IL-6 is an example of a multifunctional cytokine involved in the mediation of the immune response and inflammation \[[@bib23],[@bib24]\]. IL-6 is produced mainly by monocytes, but also be produced by interstitial fibroblasts and alveolar macrophages in the lung \[[@bib25],[@bib26]\]. IL-6 has also been shown to be involved in the pathogenesis of acute lung injury \[[@bib27]\]. Histological characteristics in the lung of COVID-19 patients showed diffuse alveolar damage and interstitial lymphocytes infiltrates \[[@bib11]\]. IL-6 may act as a functional mediator to recruit lymphocytes into the lung lesions, which can further secrete IL-6 in a vicious cycle, thus aggravating the lung injury and hastening death.

Early clinical and laboratory factors contributing to disease severity were advanced age, sputum production, shortness of breath, elevated neutrophil count, AST, LDH and GGT levels, elevated CRP and ESR, high serum ferritin level, increased interleukin-6 and D-dimer. In the binary logistic regression model C-reactive protein level (OR 1.073,\[CI, 1.013--1.136\]; p = 0.017), CD8^+^ T lymphocyte count(OR 0.989,\[CI, 0.979--1.000\]; p = 0.043), and D-dimer (OR 5.313,\[CI, 0.325--86.816\]; p = 0.241) were independent predictors of disease severity. D-dimer did not reach statistical significance possibly due to its effect on other factors.

3. Conclusions {#sec3}
==============

COVID-19 primarily attacks the lungs, but other organ systems can sustain injury as well, including the heart and liver. Disease severity increased with advancing age. Our findings indicated that C-reactive protein level, CD8 T lymphocyte count, and D-dimer were independent predictors of disease severity in COVID-19 patients in Beijing.
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